Collegium Pharmaceutical (COLL) Capital Expenditures (2015 - 2026)

Collegium Pharmaceutical's Capital Expenditures history runs 12 years deep, the most recent figure standing at $207000.0 for Q1 2026.

• On a quarterly basis, Capital Expenditures fell 74.06% year-over-year to $207000.0 in Q1 2026; TTM through Mar 2026 was -$272000.0, a 165.54% decrease from a year earlier, with the FY2025 full-year figure at $319000.0, up 72.43% from the prior year.
• Capital Expenditures rose to $207000.0 in Q1 2026 per COLL's latest filing, from -$732000.0 in the prior quarter.
• Across five years, Capital Expenditures topped out at $940000.0 in Q4 2022 and bottomed at -$897000.0 in Q4 2024.
• The 5-year median for Capital Expenditures is $164000.0 (2023), against an average of $164352.9.
• Biggest YoY gain for Capital Expenditures was 1256.92% in 2024; the steepest drop was 757.14% in 2024.
• Year by year, Capital Expenditures stood at $940000.0 in 2022, then tumbled by 82.55% to $164000.0 in 2023, then slumped by 646.95% to -$897000.0 in 2024, then gained by 18.39% to -$732000.0 in 2025, then soared by 128.28% to $207000.0 in 2026.
• Per Business Quant, the three latest COLL Capital Expenditures figures stand at $207000.0 (Q1 2026), -$732000.0 (Q4 2025), and $188000.0 (Q3 2025).